



# Attruby in India

The CDSCO named-patient coordination pathway — indicative 2026

RARE DISEASE · ATTR CARDIOMYOPATHY

## The clinical situation

Attruby (acoramidis) is an oral selective TTR stabiliser FDA-approved for the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults, to reduce cardiovascular death and cardiovascular-related hospitalisation. Manufactured by BridgeBio. Attruby is dosed at 712 mg twice daily, binding and stabilising the TTR tetramer with near-complete occupancy. Pre-treatment workup covers ATTR-CM diagnostic confirmation (PYP scintigraphy or biopsy), TTR genotype for hereditary form, and cardiac baseline per FDA labelling.

### The pathway, 5 steps

- 1 Consultation & clinical rationale.** Your cardiologist documents ATTR-CM diagnosis via PYP scintigraphy or biopsy, TTR genotype, NYHA class, and Attruby rationale.
- 2 Baseline workup.** LFTs, renal function, cardiac baseline (echo, NT-proBNP, troponin), ECG per FDA labelling.
- 3 CDSCO named-patient application.** Physician or hospital pharmacy files clinical rationale, patient reference, and chain-of-custody commitment.
- 4 US-side sourcing & logistics.** Reserve Meds coordinates product through our US-licensed DSCSA-compliant specialty wholesale partner with controlled-ambient shipment.
- 5 Arrival & first dose.** Dispensing pharmacy releases the first 30-day supply; monthly refill cadence established.

### Indicative economics

**Reference US cash-pay range:** USD 200,000–240,000 per year of Attruby (drug-only reference; Reserve Meds provides a transparent delivered quote at intake).

### Indicative first-dose timing

**7–14 days** from a complete CDSCO application to first dispensation, once cohort intake opens. Indicative — not guaranteed.

## Reserve Meds's role

**Sourcing.** US-licensed specialty wholesale partner, DSCSA chain-of-custody from BridgeBio authorised distribution.

**Documentation.** Physician kit tailored to CDSCO review, with ATTR-CM diagnostic confirmation annex. **Logistics.** Controlled-ambient internationally tracked shipment. **Concierge case lead.** Named point of contact for family and physician through monthly refills. **We are a coordinator** — not the prescriber, not the dispensing pharmacy. All clinical decisions remain with your treating physician.

**COMPOSITE EXAMPLE · PRE-LAUNCH WAITLIST**

**Join the Attruby × India first-cohort waitlist.** *Our concierge reaches out as we open intake.*

[reservemed.com/access-guides/attruby-india.html](https://reservemed.com/access-guides/attruby-india.html)



SCAN TO JOIN

**Reserve Meds** · US-based concierge for cross-border specialty medicine. We are a coordinator; we are not the prescriber and not the dispensing pharmacy. All clinical decisions remain with the treating physician. Not medical advice.

*Reserve Meds is in pre-launch. Service availability is limited to our first cohort; all timelines published are indicative, not guarantees. Composite case examples only.*

**reservemed.com** · [hello@reservemed.com](mailto:hello@reservemed.com) · WhatsApp concierge: +1 516 528 3120 · Reviewed 2026-04-23 by Reserve Meds clinical & regulatory team